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Abstract
Background: Allogeneic stem cell transplantation is the only curative option for patients with acute myeloid
leukemia (AML) experiencing relapse. Either matched sibling donor (MSD) or unrelated donor (UD) is indicated.
Methods: We analyzed 1554 adults with AML transplanted from MSD (n = 961) or UD (n = 593, HLA-matched 10/10,
n = 481; 9/10, n = 112). Compared to MSD, UD recipients were older (49 vs 52 years, p = 0.001), transplanted more
recently (2009 vs 2006, p = 0.001), and with a longer interval to transplant (10 vs 9 months, p = 0.001). Conditioning
regimen was more frequently myeloablative for patients transplanted with a MSD (61 vs 46 %, p = 0.001). Median
follow-up was 28 (range 3–157) months.
Results: Cumulative incidence (CI) of neutrophil engraftment (p = 0.07), grades II–IV acute GVHD (p = 0.11), chronic
GVHD (p = 0.9), and non-relapse mortality (NRM, p = 0.24) was not different according to the type of donor. At 2 years,
CI of relapse (relapse incidence (RI)) was 57 vs 49 % (p = 0.001). Leukemia-free survival (LFS) at 2 years was 21 vs 26 %
(p = 0.001), and overall survival (OS) was 26 vs 33 % (p = 0.004) for MSD vs UD, respectively. Chronic GVHD as
time-dependent variable was associated with lower RI (HR 0.78, p = 0.05), higher NRM (HR 1.71, p = 0.001), and higher
OS (HR 0.69, p = 0.001). According to HLA match, RI was 57 vs 50 vs 45 %, (p = 0.001) NRM was 23 vs 23 vs 29 %
(p = 0.26), and LFS at 2 years was 21 vs 27 vs 25 % (p = 0.003) for MSD, 10/10, and 9/10 UD, respectively. In multivariate
analysis adjusted for differences between the two groups, UD was associated with lower RI (HR 0.76, p = 0.001) and
higher LFS (HR 0.83, p = 0.001) compared to MSD. Interval between diagnosis and transplant was the other factor
associated with better outcomes (RI (HR 0.62, p < 0.001) and LFS (HR 0.67, p < 0.001)).
Conclusions: Transplantation using UD was associated with better LFS and lower RI compared to MSD for high-risk
patients with AML transplanted in first relapse.
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Background
Although the outcome of patients diagnosed with acute
myeloid leukemia (AML) has improved, disease recur-
rence remains the leading cause of treatment failure,
with only a minority of patients who durably benefit
from current reinduction therapies. For patients achiev-
ing complete remission (CR) after salvage chemotherapy,
the overall relapse risk is nearly 45–50 %, but this is
highly variable and is primarily determined by the biol-
ogy of the disease [1]. For patients with AML, allogeneic
hematopoietic stem cell transplantation (HSCT) is a
curative option. Recent improvements in donor availabil-
ity, conditioning regimens, and supportive care broad-
ened the applicability of HSCT in nearly all patients
with AML with better long-term outcomes. Moreover,
the use of post-transplant immunomodulating strategies
allowed long-term survival and better disease control.
Both myeloablative (MAC) and reduced-intensity (RIC)
conditioning regimens are suitable options for treating
these patients allowing disease control. In the MAC setting,
regimens containing either busulfan or total body irradi-
ation (TBI) are effective for refractory AML with a reported
2-year leukemia-free survival (LFS) of less than 30 % with
both regimens [2]. On the other hand, the introduction of
RIC made HSCT feasible even in elderly or in young
patients with significant comorbidities, not eligible for
standard MAC [3]. However, post-transplant relapse re-
mains a challenge in RIC, especially in high-risk patients
with AML in primary relapse.
In this setting, donor search might be started as soon
as possible. For patients lacking a full-matched sibling
donor (MSD), 35–40 % may have an unrelated donor
(UD) available in donor registries [4]. Prior studies
reported comparable results of HSCT from MSD versus
UD [5]; however, up to date, no studies investigated the
outcomes of patients transplanted from either a MSD or
UD for AML in first relapse.
Understanding the impact of donor source in patients
with active disease represents an area of active investiga-
tion and might be critical in the therapeutic decision-
making process. With this background, we analyzed
patients with AML in first relapse reported to the
European Society for Blood and Marrow Transplantation
(EBMT) registry from 2000 to 2012.
Methods
Study design and definition
We retrospectively analyzed adult patients (≥18 years) diag-
nosed with AML who underwent their first allogeneic
HSCT in primary relapse between 2000 and 2012, using
either a MSD or matched 10/10 or mismatched 9/10 UD.
Patients transplanted using cord blood or haploidentical
donors were excluded to homogenously compare adult
full-matched sibling or unrelated donors. The EBMT
registry is a voluntary working group of more than 500
transplant centers, mostly located in Europe, that are
required to report all consecutive HSCT and follow-up data
once a year. Audits are routinely undertaken to establish
the accuracy of the data.
Karyotype abnormalities were classified as favorable,
intermediate or high risk as previously described [6].
Conditioning regimen was MAC in case of administration
of total body irradiation (TBI) at a dose greater than 6 Gray
(Gy), oral busulfan greater than 8 mg/kg, or intravenous
busulfan greater than 6.4 mg/kg. All patients provided
informed consent for transplant according to the declar-
ation of Helsinki. The Review Board of the EBMTapproved
this study.
Definitions and end points of the study
The primary endpoint of the study was LFS according to
the type of donor (MSD vs UD). Secondary endpoints
included overall survival (OS), neutrophil engraftment,
acute and chronic graft versus host disease (GVHD), non-
relapse mortality (NRM), and relapse incidence (RI). LFS
was calculated from the date of transplant until relapse or
last disease-free follow-up. Neutrophil engraftment was
defined as achieving absolute neutrophil count ≥0.5 × 109/
l for three consecutive days. The diagnosis and grading of
acute and chronic GVHD was performed using the stand-
ard criteria [7]. Relapse and death from any cause were
considered events. NRM was defined as death without
prior relapse.
Statistical analyses
Median values and ranges were used for continuous vari-
ables and percentages for categorical variables. Patient-,
disease-, and transplant-related variables of the groups were
compared using Chi-square or Fischer exact test for
categorical variables, and Mann–Whitney test for continu-
ous variables. The probabilities of OS and LFS were calcu-
lated using the Kaplan–Meier [8] method and the log-rank
test for univariate comparisons.
Neutrophil engraftment, grades II–IV acute and chronic
GVHD, relapse, and NRM were calculated by using the
cumulative incidence (CI) estimator to accommodate com-
peting risks. For NRM, relapse was the competing risk, and
for relapse, the competing risk was NRM.
Multivariate analyses adjusted for differences between
the groups were performed using Cox proportional
hazards regression model for LFS and OS, and Fine and
Gray’s [9] proportional hazards regression model for
engraftment, GVHD, NRM, and relapse. Chronic GVHD
was analyzed as time-dependent factor using Cox model
for LFS and OS. p values were two-sided. Statistical ana-
lyses were performed with the SPSS 19 (SPSS Inc./IBM,
Armonk, NY, USA) and R 3.0 (R Development Core
Team, Vienna, Austria) software packages.
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Results
Patient and transplant characteristics
Baseline characteristics are summarized in Table 1. Briefly,
1554 patients fulfilling the inclusion criteria were identified;
of these, 961 were transplanted with a MSD and 481 with
an UD (HLA-matched 10/10, n = 481, 9/10, n = 112).
There were some differences between the two groups: UD
recipients were older (52 vs 49 years; p < 0.001) and they
underwent HSCT more recently (2006 vs 2009 for UD
recipients; p < 0.001) compared to MSD recipients. Time
from diagnosis to HSCT was longer for UD recipients (10
vs 8 months, p < 0.001). A slightly higher proportion of
secondary AML was observed in the MSD group (125 vs
113 in the UD group, p < 0.003).
The majority of the patients underwent a MAC regimen,
especially in the MSD group (60 vs 46 % for the UD group,
p < 0.001); 186 patients received a combination of a short
intensive course of chemotherapy, followed by a RIC
regimen (FLAMSA-regimen) as previously described [10],
including 125 TBI-containing and 66 busulfan-containing
regimen. In vivo T cell depletion was more frequently used
in UD group (99 vs 75 %, p < 0.001). Ninety percent of
patients in both groups (p = 0.14) received peripheral blood
cells (PBSC) as stem cell source.
Engraftment, acute, and chronic GVHD
The CI of neutrophil engraftment was 93 vs 92 % in
MSD and UD recipients, respectively (p = 0.07). The me-
dian time for neutrophil engraftment was of 15 days
(range 6–90), with no difference between the groups.
Graft failure occurred in nearly 5 % of patients in each
group (p = 0.73).
According to the type of donor CI of day-100 grades II–
IV acute GVHD was 26 vs 30 % (p = 0.11), in MSD and
UD, respectively. There was no difference in the CI of
chronic GVHD at 2 years in the 2 groups (25 %, p = 0.90).
Relapse and NRM
Within 100 days after HSCT, 72 % (n = 403) of UD
recipients achieved CR, versus 66 % (n = 586) in MSD
group (p = 0.02).
At 2 years, CI of relapse was higher in MSD recipients
(57 vs 49 % in UD recipients, p < 0.001), while NRM was
similar in the two groups (23 % in MSD vs 24 % in UD,
p = 0.24) (Fig. 1a, b).
In multivariate analysis (Table 2), patients transplanted
with UD (HR= 0.76, 95 % CI 0.64–0.89; p < 0.001), and
those with a longer interval between diagnosis and HSCT
(HR= 0.62, 95 % CI 0.53–0.72; p < 0.001) showed lower re-
lapse. RIC regimen was independently associated with
higher relapse (HR = 1.21, 95 % CI 1.02–1.42; p < 0.03).
Also, chronic GVHD as time-dependent variable was inde-
pendently associated with a lower RI (HR = 0.78, 95 % CI
0.61–1.00; p < 0.05) and a higher NRM (HR= 1.71, 95 % CI
Table 1 Patient, disease, and transplant characteristics
Characteristic (%) MSD (n = 961) UD (n = 593) p value
Median follow-up, months 30 (1–157) 27 (1–137) 0.28
Median age, years (range) 49 (18–75) 52 (18–77) <0.01
Median year of HSCT (range) 2006 (2000–2012) 2009 (2000–2012) <0.01
Interval from diagnosis
to HSCT, months (range)
8.6 (2–155) 10.3 (2.5–186) <0.01
De novo AML 836 (87) 480 (81) <0.01
sAML 125 (13) 113 (19)
Prior auto-HSCT 57 (6) 41 (7) 0.59
Donor’s gender
Male 500 (52) 417 (72) <0.01
Female 452 (48) 162 (28)
CMV positive serostatus <0.01
Patient 472 (69) 210 (37)
Donor 417 (62) 244 (42)
Conditioning regimen
MAC 559 (60) 269 (46) <0.01
RIC 365 (40) 316 (54)
Conditioning details
BuCy 155 (16) 81 (14) <0.01
BuFlu 135 (14) 112 (19)
FluMel 89 (9) 81 (14)
Threo-based 36 (4) 26 (4)
MAC TBI 178 (1) 79 (13)
RIC TBI 32 (3) 13 (2)
Other 336 (35) 201 (34)
Stem cell source
BM 107 (11) 60 (10) 0.14
PBSC 854 (89) 533 (90)
GVHD prophylaxis
CsA alone 115 (12) 81 (14) <0.01
CsA +MMF 182 (19) 187 (31)
CsA + MTX 362 (38) 246 (41)
Other 68 (7) 75 (13)
Missing 234 (24) 4 (1)
In vivo TCD <0.01
ATG 167 (17) 388 (65)
Alemtuzumab 20 (2) 47 (8)
No 521 (54) 154 (26)
Missing 235 (24) 4 (1)
Abbreviations: MSD matched sibling donor, UD unrelated donor, HSCT
hematopoietic stem cell transplantation, sAML secondary acute myeloid
leukemia, auto-HSCT autologous stem cell transplantation, CMV cytomegalovirus,
MAC myeloablative conditioning regimen, RIC reduced-intensity conditioning
regimen, Bu busulfan, Cy cyclophosphamide, Flu fludarabine, Mel melphalan,
Threo threosulfan, TBI total body irradiation, BM bone marrow, PBSC peripheral
blood stem cells, CsA cyclosporine A, MMF mycophenolate mophetil, MTX
methotrexate, TCD T-cell depletion, ATG antithymocyte globulin
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1.18–2.48; p < 0.001). Causes of death are reported in
Table 3.
LFS and OS
With a median follow-up of 2.4 (range 0.3–13) years, the
2 years probability of LFS was 21 vs 26 % (p < 0.001) and
OS was 26 vs 33 % (p < 0.004) for MSD and UD recipients,
respectively (Fig. 1c, d). In adjusted multivariate analysis
(Table 2), LFS was higher for patients transplanted with UD
(HR= 0.83, 95 % CI 0.72–0.96; p < 0.01) and for those with
a shorter interval between diagnosis and HSCT (HR= 0.67,
95 % CI 0.59–0.77; p < 0.001). Chronic GVHD as time-
dependent variable was associated with higher OS (HR =
0.69, 95 % CI 0.56–0.84; p < 0.001), and no differences were
observed for LFS (HR = 0.99, 95 % CI 0.80–1.21; p = 0.90).
Outcomes according to HLA-match
We performed a subgroup analysis to evaluate out-
comes according to HLA disparity (UD 10/10 or 9/10
as compared to MSD). There were no differences for
neutrophil engraftment (92 vs 89 vs 93 %, p = 0.20),
chronic GVHD (25 % in all groups, p = 0.96), and NRM
(23 vs 23 vs 30 %, p = 0.26) between the three groups. CI of
relapse was higher for MSD as compared to 10/10 or 9/10
UD (57 vs 50 vs 45 %, p = 0.0003). Patients in the MSD
group had lower LFS (20 % in MSD vs 27 % in 10/10 and
25 % in 9/10 UD, p = 0.003), and lower OS (26 % in MSD
vs 34 % in 10/10 and 29 % in 9/10 UD, p = 0.01). No differ-
ences were found in the multivariate analysis (Table 4) for
MSD versus 9/10 UD for RI (HR = 0.77, 95 % CI 0.57–1.05;
p = 0.10), NRM (HR= 1.32, 95 % CI 0.87–2.00; p = 0.19),
LFS (HR = 0.92, 95 % CI 0.72–1.18; p = 0.53), and OS
(HR = 1.00, 95 % CI 0.78–1.29; p = 0.99).
Discussion
AML recurrence still represents one of the most difficult
scenarios associated with poor prognosis. Most patients
often do not respond to reinduction therapies which are
also hampered by toxicities. This might leave patients
unfit for additional therapies. On the other hand, HSCT
is a treatment strategy that may offer possibility of cure,
although survival does not exceed 20 to 35 % at 4 years
[11, 12]. The increased availability of donors, the use of
non-myeloablative or RIC regimens, and the progress in
a b
c d
Fig. 1 a Relapse incidence. b Non-relapse mortality. c Leukemia-free survival. d Overall survival by type of donor
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supportive care, translating in survival improvements,
made HSCT available and possible in almost all patients.
Therefore, a rapid donor search should be promptly
initiated in high-risk AML patients [4].
In the present study, we compared the outcomes of
patients undergoing allogeneic HSCT for AML in
primary relapse either from a MSD or from a matched
or single-allele mismatched UD.
Several retrospective studies on patients transplanted
with active disease have been reported. The French
Society of Bone Marrow Transplantation (SFGM)
reported outcomes of 379 patients transplanted for
high-risk AML with a 5-year probability of LFS
approximately of 10 %. In multivariate analysis the use
of a matched or mismatched UD was associated with
lower OS [13].
Few retrospective studies or case series limited to a
small subset of highly selected patients receiving a MAC
HSCT for active AML have been reported in the literature
[13, 14]: a large CIBMTR study in AML in relapse or
primary induction failure showed a 3-year OS of 19 %.
The German Transplant Study in 113 patients under-
going a RIC transplant showed a probability of LFS of
49 % for patients with less than 5 % bone marrow blasts
and 14 % for those with more than 20 % marrow blasts
at time of HSCT [15]. Moreover, patients transplanted
from a MSD had better event-free survival as compared
to patients transplanted from UD. A phase II study from
van Besien et al. in patients with AML or myelodysplas-
tic syndrome included 28 patients with active AML
undergoing a RIC transplant with fludarabine, melpha-
lan, and alemtuzumab, with a 1-year LFS of 25 %. No
differences were found in the whole population out-
comes according to the type of donor [16].
In our cohort, we observed that patients undergoing a
RIC had a higher risk of relapse when compared to MAC
transplant, in accordance with previous reports [17, 18].
Table 2 Multivariate analysis for patients with AML in primary
relapse
Variable HR (95 % CI) p
RI
UD vs MSD 0.76 (0.64–0.89) <0.01
Agea 0.99 (0.99–1.00) 0.02
Time from dx to Tx >9 months 0.62 (0.53–0.72) <0.01
Female donor to male recipient 0.91 (0.74–1.11) 0.35
sAML 0.99 (0.79–1.23) 0.92
previous auto-HSCT 1.22 (0.86–1.73) 0.26
Positive recipient CMV serology 0.96 (0.80–1.15) 0.68
Positive donor CMV serology 1.03 (0.86–1.22) 0.77
RIC 1.21 (1.02–1.42) 0.03
NRM
UD vs MSD 1.04 (0.80–1.35) 0.79
Agea 1.02 (1.01–1.03) <0.01
Time from dx to Tx >9 months 0.82 (0.64–1.06) 0.12
Female donor to male recipient 0.86 (0.62–1.21) 0.40
sAML 1.39 (1.03–1.87) 0.03
previous auto-HSCT 1.49 (0.91–2.43) 0.11
Positive recipient CMV serology 0.98 (0.74–1.30) 0.89
Positive donor CMV serology 0.98 (0.74–1.28) 0.86
RIC 0.96 (0.74–1.24) 0.74
LFS
UD vs MSD 0.83 (0.72–0.96) 0.01
Agea 1.00 (0.99–1.00) 0.82
Time from dx to Tx >9 months 0.67 (0.59–0.77) <0.01
Female donor to male recipient 0.90 (0.75–1.07) 0.22
sAML 1.11 (0.93–1.32) 0.26
previous auto-HSCT 1.29 (0.97–1.71) 0.08
Positive recipient CMV serology 0.97 (0.84–1.13) 0.72
Positive donor CMV serology 1.01 (0.87–1.17) 0.87
RIC 1.13 (0.98–1.30) 0.09
OS
UD vs MSD 0.89 (0.77–1.03) 0.12
Agea 1.00 (1.00–1.01) 0.36
Time from dx to Tx >9 months 0.71 (0.61–0.81) <0.01
Female donor to male recipient 0.86 (0.72–1.03) 0.10
sAML 1.09 (0.91–1.31) 0.34
previous auto-HSCT 1.25 (0.93–1.68) 0.15
Positive recipient CMV serology 0.96 (0.82–1.12) 0.61
Positive donor CMV serology 0.99 (0.85–1.16) 0.92
RIC 1.01 (0.88–1.17) 0.88
Abbreviations: HR hazard ratio, CI confidence interval, RI relapse incidence,
NRM non-relapse mortality, LFS leukemiafree survival, OS overall survival,
UD unrelated donor, MSD matched sibling donor, cont continuous,
dx diagnosis, tx transplant, sAML secondary acute myeloid leukemia, auto-HSCT
autologous hematopoietic stem cell transplantation, CMV cytomegalovirus,
RIC reduced-intensity conditioning regimen
aAs continuous variable
Table 3 Causes of death for patients with MSD and UD
MSD UD
Cardiac toxicity 3 (0.4 %) 3 (0.8 %)
Hemorrhage 12 (1.7 %) 5 (1.3 %)
Failure/Rejection 3 (0.4 %) 1 (0.3 %)
Veno Occlusive Disease 11 (1.6 %) 14 (3.7 %)
Infection 105 (15.1 %) 64 (16.8 %)
Interstitial Pneumonia 11 (1.6 %) 7 (1.8 %)
Graft versus host disease 72 (10.4 %) 50 (13.1 %)
Original disease 436 (62.3 %) 222 (58.1 %)
Secondary malignancy 2 (0.3 %) 0 (0 %)
Other transplant related 32 (4.6 %) 9 (2.4 %)
Multi Organ Failure 8 (1.2 %) 7 (1.8 %)
Unknown 14 5
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Some of the patients in the current study received a
sequential regimen: however, numbers were too small
to analyze the impact of this regimen on HSCT
outcomes.
Compared to MSD recipients, in our series patients
transplanted with UD experienced higher OS, LFS, and
lower RI. This was confirmed in the multivariate
analysis, where the type of donor was an independent
risk factor for LFS and relapse incidence. This could be
related to a stronger graft versus leukemia (GVL) effect
in the UD group due to a higher likelihood of
mismatches in minor histocompatibility antigens [19].
Increase in GVHD in case of UD is reported both in
the MAC and RIC setting, with a correlation between
severity of GVHD and HLA mismatch (29). Importantly
in our series, acute and chronic GVHD were not differ-
ent either according to the type of donor or to HLA
mismatches. However, given the retrospective nature of
our study, we were not able to evaluate the effect of the
single-allele mismatch and the HLA locus for addressing
the GVL effect.
In the UD setting, a lower incidence of relapse in pa-
tients experiencing chronic GVHD has been reported
[20]. Of note, in our series, in accordance with previous
reports [21], chronic GVHD as a time-dependent vari-
able was associated with lower risk of RI and higher OS.
Similar results were found by Lee et al. who reported a
better disease control in extensive as compared to
limited chronic GVHD, this being counterbalanced by
morbidity from chronic GVHD [22].
When focusing on conditioning intensity, Weisdorf et al.
reported a longer GVL benefit in patients experiencing
GVHD after a RIC transplant as compared to patients
undergoing a MAC transplant [23]. This study highlights
the importance of immune modulation, especially in the
context of RIC transplant.
Importantly, improvements in supportive care after
HSCT over the years, including the advent of new anti-
fungal and antiviral drugs, allowed better survival and
reduction of NRM, with a wider number of patients
eligible for post-transplant immune modulation with
better disease control.
Table 4 Multivariate analysis for patients with AML in primary
relapse according to HLA mismatch
Variable HR (95 % CI) p
RI
UD 10/10 0.75 (0.63–0.90) <0.01
UD 9/10 0.77 (0.57–1.05) 0.10
Agea 0.99 (0.99–1.00) 0.02
Time from dx to Tx >9 mo 0.62 (0.52–0.72) <0.01
Female donor to male recipient 0.91 (0.74–1.11) 0.34
sAML 0.99 (0.79–1.23) 0.92
previous auto-HSCT 1.22 (0.86–1.73) 0.26
Positive recipient CMV serology 0.96 (0.80–1.15) 0.68
Positive donor CMV serology 1.03 (0.86–1.22) 0.77
RIC 1.21 (1.02–1.42) 0.03
NRM
UD 10/10 0.97 (0.74–1.29) 0.86
UD 9/10 1.32 (0.87–2.00) 0.19
Agea 1.02 (1.01–1.03) <0.01
Time from dx to Tx >9 mo 0.81 (0.62–1.04) 0.10
Female donor to male recipient 0.86 (0.61–1.20) 0.38
sAML 1.40 (1.04–1.90) 0.03
previous auto-HSCT 1.50 (0.92–2.45) 0.10
Positive recipient CMV serology 0.96 (0.72–1.28) 0.80
Positive donor CMV serology 0.98 (0.75–1.29) 0.90
RIC 0.96 (0.74–1.25) 0.78
LFS
UD 10/10 0.81 (0.70–0.94) 0.01
UD 9/10 0.92 (0.72–1.18) 0.53
Agea 1.00 (0.99–1.00) 0.82
Time from dx to Tx >9 mo 0.67 (0.58–0.76) <0.01
Female donor to male recipient 0.89 (0.75–1.07) 0.21
sAML 1.11 (0.93–1.33) 0.24
previous auto-HSCT 1.30 (0.98–1.72) 0.07
Positive recipient CMV serology 0.97 (0.83–1.13) 0.67
Positive donor CMV serology 1.01 (0.88–1.17) 0.86
RIC 1.13 (0.98–1.30) 0.08
OS
UD 10/10 0.87 (0.74–1.01) 0.07
UD 9/10 1.00 (0.78–1.29) 0.99
Agea 1.00 (1.00–1.01) 0.36
Time from dx to Tx >9 mo 0.70 (0.61–0.81) <0.01
Female donor to male recipient 0.85 (0.71–1.03) 0.09
sAML 1.10 (0.91–1.32) 0.31
previous auto-HSCT 1.25 (0.93–1.69) 0.14
Table 4 Multivariate analysis for patients with AML in primary
relapse according to HLA mismatch (Continued)
Positive recipient CMV serology 0.95 (0.81–1.12) 0.56
Positive donor CMV serology 0.99 (0.85–1.16) 0.94
RIC 1.01 (0.88–1.17) 0.86
Abbreviations: HR hazard ratio, CI confidence interval, RI relapse incidence, NRM
non-relapse mortality, LFS leukemia-free survival, OS overall survival, UD unrelated
donor, MSD matched sibling donor, cont continuous, dx diagnosis, tx transplant,
sAML secondary acute myeloid leukemia, auto-HSCT autologous hematopoietic
stem cell transplantation, CMV cytomegalovirus, RIC reduced-intensity
conditioning regimen
aAs continuous variable
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One may argue that patients receiving RIC may have
benefit of earlier withdrawal of immunosuppressive
treatment or post HSCT maintenance therapy, or donor
lymphocyte infusion and therefore without differences in
LFS. However, we did not investigate the type of post
HSCT strategy, being related to the different transplant
policy.
We confirm that the interval from diagnosis to HSCT
was one of the factors associated with relapse, LFS, and
OS, independently from the type of donor, highlighting
the need to rapidly look for a donor and perform HSCT
early to ensure long-term disease control. The place of
unmanipulated haploidentical donor transplant need to
be considered in this setting to establish the adapted
algorithm for donor selection in this setting of patients.
Our study has some limitations as a retrospective registry
analysis. Although patients were categorized by their
disease biology and the multivariate modeling may have
adjusted for various patient-, disease-, and transplantation-
related factors, there may be factors of importance that we
have not been able to take into account, such as the reason
why those patients were not transplanted in first CR.
Further studies are needed to highlight the place of
sequential approach in such a high-risk patients with
otherwise limited options, as reported also using other
regimen combination [24], and other post-transplant
strategies such as early withdrawal of immunosuppres-
sive treatment and immunomodulating agents or
preemptive use of donor lymphocyte infusions should be
considered early in this high-risk population to enhance
long-term disease control.
Conclusions
Our data suggest that the use of UD is feasible and ef-
fective in patients with AML undergoing allogeneic
HSCT in primary relapse, with even better outcomes in
terms of LFS, RI and OS in patients transplanted from
MSD. The role of one antigen mismatch UD in this set-
ting should be evaluated in a larger and more
homogenous series. Moreover, as timing to HSCT still
remains one of the most important factors influencing
transplant outcomes, it is important to promptly start
donor search on the registries when a MSD is not avail-
able, in order to identify a suitable UD. Our data con-
firm that a strong disease control is possible with a
single-allele mismatched UD with no increased toxicity.
In patients not eligible for a full intensity regimen, use
of RIC regimens, might be a valid option to improve
disease control and survival. Despite better results for
patients given UD, outcome of patients transplanted in
primary relapse is still not satisfactory. Further prospect-
ive studies investigating the implementation of post-
transplant immunomodulating strategies are warranted
in this high-risk subset of patients.
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